The company has managed to raise USD 70 million, which it will use to progress its lead candidate…

Through this certified status, the CDMO will be able to offer its customers targeted, multiplex protein biomarker analysis…

Although the trial did not meet its primary endpoint, EyePoint reported a 42% reduction in overall treatment burden,…

Ahead of CPHI Milan 2026, Professor Hanns-Christian Mahler from ten23 health, explores how expanding dose volumes, flexible CDMO…

As demand for patient-centric chronic disease treatments grows, Nanexa CTO Mårten Rooth discusses how atomic layer deposition enables…

As biopharma moves beyond traditional batch processing, industry leaders evaluate how the FDA’s Advanced Manufacturing Technology designation program…

A global licensing agreement worth up to EUR 1.165 billion will leverage Nanexa's PharmaShell technology to develop long-acting…

The Minnesota injectables CDMO has signed a technical transfer and manufacturing agreement for a currently marketed, high-viscosity injectable,…

Through this acquisition, Eli Lilly will strengthen its immunology capabilities by gaining access to a first-in-class antibody-degradation platform…

The U.S. regulatory body has approved AstraZeneca’s Etcamah in combination with CDK4/6 inhibitors, to treat adults with HR‑positive,…

A combination therapy from Gilead and Merck has met its clinical efficacy endpoint, demonstrating non-inferiority to existing daily…

AstraZeneca’s camizestrant has faced a regulatory setback in the U.S., with the FDA extending its review, seeking clearer…

SPONSORED CONTENT: As the biopharmaceutical landscape increasingly demands integrated technical operations, GCCs are expanding beyond back-office efficiency, reveals…

As the divide between upstream output and downstream capability in bioprocessing expands, it is becoming necessary for the…

Experts from Alcami break down the latest innovations in lipid-based permeation matrices, continuous direct compression, and advanced analytical…